Literature DB >> 32360164

How common is repeat surgery and multi-level treatment in Degenerative Cervical Myelopathy? Findings from a patient perspective survey.

Aref-Ali Gharooni1, Ben Grodzinski2, Benjamin M Davies3, Mark R N Kotter4.   

Abstract

Degenerative Cervical Myelopathy (DCM) is a common condition which causes significant disability and reduces health-related quality of life. The only evidence-based treatment and current management guidance is surgery to decompress the spinal cord and stop further damage in moderate to severe cases. However, this guidance is mainly informed by studies that only include first time surgery and/or single level disease, but DCM can reoccur after primary surgery and affect multiple levels of the spine. It is unclear whether patients in these subgroups; repeat surgery and multi-level DCM, differ significantly in their baseline and disease characteristics from those with single-level, single-operation disease. To investigate this, we conducted an online survey of people with DCM looking at key demographic, disease (e.g. mJOA) and treatment characteristics. We received a total of 778 respondents, of which 159 (20%) had undergone surgery for DCM. Around 75% of these respondents had a single operation and 65% at a single level. We found no statistically significant difference in key participant and disease characteristics between respondents with single-level or single-operation and those with multi-level DCM or multiple operations. These data support generalisability of research to these subgroups but also warrants further investigations as these subgroups are underrepresented in current research.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cervical Spondylosis; Degenerative Cervical Myelopathy; Multi-level; Repeat surgery; Revision surgery; Surveys and Questionnaires

Mesh:

Year:  2020        PMID: 32360164     DOI: 10.1016/j.jocn.2020.04.109

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  2 in total

1.  Developing Novel Therapies for Degenerative Cervical Myelopathy [AO Spine RECODE-DCM Research Priority Number 7]: Opportunities From Restorative Neurobiology.

Authors:  Aref-Ali Gharooni; Brian K Kwon; Michael G Fehlings; Timothy F Boerger; Ricardo Rodrigues-Pinto; Paul Aarne Koljonen; Shekar N Kurpad; James S Harrop; Bizhan Aarabi; Vafa Rahimi-Movaghar; Jefferson R Wilson; Benjamin M Davies; Mark R N Kotter; James D Guest
Journal:  Global Spine J       Date:  2022-02

2.  The development of lived experience-centered word clouds to support research uncertainty gathering in degenerative cervical myelopathy: results from an engagement process and protocol for their evaluation, via a nested randomized controlled trial.

Authors:  Benjamin M Davies; Oliver D Mowforth; Danyal Z Khan; Xiaoyu Yang; Sybil R L Stacpoole; Olesja Hazenbiller; Toto Gronlund; Lindsay Tetreault; Sukhvinder Kalsi-Ryan; Michelle L Starkey; Iwan Sadler; Ellen Sarewitz; Delphine Houlton; Julia Carter; Evangeline Howard; Vafa Rahimi-Movaghar; James D Guest; Bizhan Aarabi; Brian K Kwon; Shekar N Kurpad; James Harrop; Jefferson R Wilson; Robert Grossman; Emma K Smith; Angus G K McNair; Michael G Fehlings; Mark R N Kotter
Journal:  Trials       Date:  2021-06-25       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.